Learning Objectives:

1.  To discuss mechanisms of cost saving on drug expenditures, independent of policy change and including interventional pharmacoeconomics.

2.  To discuss the interventional pharmacoeconomic approach for tocilizumab in COVID-19.

3.  To discuss early data exploring ambiguity aversion in oncologists.

Session date: 
11/16/2020 - 12:00pm to 1:00pm CST
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Garth W. Strohbehn, MD, MPhil